Ken Reali | Co-Founder & CEO |
Greg Anglum | CFO |
Drew Ranieri | Morgan Stanley |
Kyle Rose | Canaccord |
Good afternoon, ladies and gentlemen and welcome to the Second Quarter 2021 Earnings Conference Call for Bioventus Inc. At this time all participants have been placed in a listen-only mode. Please note that this call is being recorded and that the recorded and that recording will be available on the company's website for replay shortly after the end of the call.
Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A of the company's Form 10-K for the year ended December 31, 2020, as well as our most recent 10-Q filing to be filed with the Securities and Exchange Commission.
You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.